Range Financial Group LLC Buys Shares of 426,095 Ironwood Pharmaceuticals, Inc. $IRWD

Range Financial Group LLC bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 4th quarter, HoldingsChannel reports. The fund bought 426,095 shares of the biotechnology company’s stock, valued at approximately $1,436,000.

Several other large investors also recently made changes to their positions in IRWD. Integrated Wealth Concepts LLC raised its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. Vise Technologies Inc. bought a new position in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets grew its holdings in Ironwood Pharmaceuticals by 83.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock worth $45,000 after buying an additional 15,594 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $48,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $57,000.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the completion of the transaction, the director owned 9,188,635 shares of the company’s stock, valued at $28,025,336.75. This trade represents a 42.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 12.70% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD opened at $3.23 on Tuesday. The stock has a market cap of $526.68 million, a price-to-earnings ratio of 24.85 and a beta of 0.24. Ironwood Pharmaceuticals, Inc. has a 12 month low of $0.53 and a 12 month high of $5.78. The stock’s 50 day moving average price is $4.06 and its 200 day moving average price is $3.17.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. The firm had revenue of $47.71 million for the quarter, compared to the consensus estimate of $86.10 million. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Citizens Jmp raised their price target on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $3.70 target price on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ironwood Pharmaceuticals currently has an average rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.